Status: Recruiting
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.
Participants needed: 7
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Hiroshima University HospitalUpdated: Apr 30, 2025Locations: 1
Eligibility criteria
Patients diagnosed with ANKL (regardless of whether the disease is first or recu...
Patients eligible to receive chemotherapy as treatment for ANKL